Search research articles
Contact Us
Filters
Showing results (161-170 of 174) with videos related to
Page
of 18
Sort By:
Blood Cancer Discovery
|
March 11, 2026
Genetic evidence against clonotypic B-lymphocytes as reservoir of plasma-cell cancers
Carmen González, Juan-Jose Garces, Hector Gracia, et al.
Leukemia
|
August 12, 2020
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials
Luciano J Costa, Benjamin A Derman, Susan Bal, et al.
The Lancet. Haematology
|
June 28, 2025
Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network
Niels W C J van de Donk, Philippe Moreau, Jesús F San-Miguel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2021
Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma
Pieter Sonneveld, Meletios A Dimopoulos, Meral Beksac, et al.
Hemasphere
|
November 27, 2025
Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network
Niels W C J van de Donk, Philippe Moreau, Jesus F San-Miguel, et al.
Haematologica
|
April 30, 2025
Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patients
Gregorio Barilà, Angela Grassi, Concetta Conticello, et al.
The Lancet. Oncology
|
May 2, 2024
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
Paula Rodriguez-Otero, Saad Usmani, Adam D Cohen, et al.
British Journal of Haematology
|
March 16, 2021
Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations
Laura Rosiñol, Meral Beksac, Elena Zamagni, et al.
The New England Journal of Medicine
|
December 12, 2023
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Pieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, et al.
Blood
|
February 28, 2025
The bone marrow NK cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy
Charlotte L B M Korst, Sabrin Tahri, Carolien Duetz, et al.
Page
of 18
Search research articles
Search
Showing results (161-170 of 174) with videos related to
Sort By:
Page
of 18
Blood Cancer Discovery
|
March 11, 2026
Genetic evidence against clonotypic B-lymphocytes as reservoir of plasma-cell cancers
Carmen González, Juan-Jose Garces, Hector Gracia, et al.
Leukemia
|
August 12, 2020
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials
Luciano J Costa, Benjamin A Derman, Susan Bal, et al.
The Lancet. Haematology
|
June 28, 2025
Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network
Niels W C J van de Donk, Philippe Moreau, Jesús F San-Miguel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2021
Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma
Pieter Sonneveld, Meletios A Dimopoulos, Meral Beksac, et al.
Hemasphere
|
November 27, 2025
Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network
Niels W C J van de Donk, Philippe Moreau, Jesus F San-Miguel, et al.
Haematologica
|
April 30, 2025
Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patients
Gregorio Barilà, Angela Grassi, Concetta Conticello, et al.
The Lancet. Oncology
|
May 2, 2024
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
Paula Rodriguez-Otero, Saad Usmani, Adam D Cohen, et al.
British Journal of Haematology
|
March 16, 2021
Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations
Laura Rosiñol, Meral Beksac, Elena Zamagni, et al.
The New England Journal of Medicine
|
December 12, 2023
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Pieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, et al.
Blood
|
February 28, 2025
The bone marrow NK cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy
Charlotte L B M Korst, Sabrin Tahri, Carolien Duetz, et al.
Page
of 18